Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Purpose: The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2008
Highly Cited
2008
Objectives:To evaluate the early tumor vasculature disrupting effects of the AVE8062 molecule and the feasibility of dynamic… Expand
Highly Cited
2007
Highly Cited
2007
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2004
Review
2004
  • P. Thorpe
  • Clinical Cancer Research
  • 2004
  • Corpus ID: 1739027
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2003
Highly Cited
2003
We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2003
2003
The in vivo combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin (CDDP) was examined. The… Expand
2003
2003
A novel combretastatin A-4 derivative, AC7700, which is now in Phase I clinical trials under a new code, AVE8062, has shown… Expand
Highly Cited
2002
Highly Cited
2002
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1999
Highly Cited
1999
The relation between tumor tissue blood flow (tBF) reduction and antitumor effects was investigated. Changes in tBF of normal… Expand
  • figure 1
  • figure 2
  • figure 3
  • table I
  • figure 4
Highly Cited
1999
Highly Cited
1999
AC‐7700, a novel combretastatin A‐4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3